Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nirmatrelvir Plus Ritonavir: First Approval.

Yvette N Lamb1

  • 1Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. dru@adis.com.

Drugs
|March 19, 2022
PubMed
Summary

Nirmatrelvir plus ritonavir (Paxlovid) offers a new treatment for COVID-19 in at-risk adults. This antiviral medication targets the SARS-CoV-2 main protease, aiding in disease management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sepiapterin: First Approval.

Drugs·2025
Same author

Tiratricol: First Approval.

Drugs·2025
Same author

Recaticimab: First Approval.

Drugs·2025
Same author

Tasurgratinib Succinate: First Approval.

Drugs·2025
Same author

Correction: Fulzerasib: First Approval.

Drugs·2025
Same author

Marstacimab: First Approval.

Drugs·2024

Area of Science:

  • Virology
  • Pharmacology
  • Infectious Diseases

Background:

  • Coronavirus disease 2019 (COVID-19) poses a significant global health challenge.
  • Effective antiviral treatments are crucial for managing COVID-19, particularly in high-risk populations.
  • Nirmatrelvir, a SARS-CoV-2 main protease inhibitor, and ritonavir, an HIV protease inhibitor and CYP3A inhibitor, have been combined for COVID-19 treatment.

Purpose of the Study:

  • To summarize the development milestones of nirmatrelvir plus ritonavir (Paxlovid).
  • To detail the drug's journey leading to its initial regulatory authorizations and approvals.
  • To highlight its role in treating COVID-19 in specific adult populations.

Main Methods:

  • Review of development history and regulatory submissions for nirmatrelvir plus ritonavir.
  • Analysis of the pharmacological action of nirmatrelvir as a protease inhibitor.
  • Examination of ritonavir's role as a pharmacokinetic enhancer and CYP3A inhibitor.

Main Results:

  • Nirmatrelvir plus ritonavir received conditional authorization in the UK in December 2021.
  • EU authorization followed in January 2022 for treating COVID-19 in adults at increased risk of severe disease.
  • Emergency use authorization was granted in the USA.

Conclusions:

  • Nirmatrelvir plus ritonavir (Paxlovid) represents a significant advancement in COVID-19 therapeutics.
  • The drug is indicated for adults not requiring supplemental oxygen but at high risk for disease progression.
  • Regulatory approvals in key regions underscore its therapeutic value in the ongoing pandemic.

Related Experiment Videos